Aman Chauhan, Leader of Neuroendocrine Cancer Program at the Sylvester Comprehensive Cancer Center, shared a post on X:
“After an exciting stretch at ESMO and NANETS, it feels great to be back in my comfort zone – the clinic. Twenty NET/NEC patients today, and two particularly interesting cases.
Lu-177 dotatate is still not accessible for lung NET patients in Canada.
There’s also growing interest (and need) for PRRT re-treatment. At NANETS 2025, we presented data showing that PRRT re-treatment is a safe and effective option for NET patients who previously benefited from PRRT.
But as always, prospective randomized data are missing. That’s exactly what the NETRetreat trial aims to address – bringing much-needed evidence to guide practice. If your site has an opportunity to open an NCTN studies, please consider adding NETRetreat to your portfolio.”
Read more posts featuring Aman Chauhan on OncoDaily.